Rivermark Medical's Significant Funding Milestone
Rivermark Medical has recently announced the successful close of a significant $30 million Series C financing round. This funding will provide crucial support in advancing the development of the FloStent™ System, which aims to offer immediate relief for patients suffering from benign prostatic hyperplasia (BPH).
The Impact of the FloStent System
The FloStent System has been designed specifically to aid in restoring urinary function in men experiencing BPH. Rivermark Medical's innovative device stands out due to its minimally invasive nature, which enables outpatient procedures that require little recovery time. With distinctive features such as quick deployment and reversibility, it prioritizes patient comfort and efficiency.
Transforming Patient Experiences
Patients suffering from BPH often face numerous challenges, including issues with frequent urination and significant discomfort during urination. The FloStent System is crafted to ease these symptoms effectively. Its unique design uses a nitinol stent, which gently expands the prostatic urethra, thereby enhancing urinary flow while also preserving sexual function—a critical aspect often overlooked in traditional treatments.
Rivermark's Vision for BPH Treatment
Adam Kadlec, the President and CEO of Rivermark Medical, expressed gratitude towards their investors for their unwavering support in this journey. He shared that the funding will play a pivotal role in accelerating their clinical programs and moving towards commercialization, ultimately benefitting countless individuals impacted by BPH.
A Bright Future for Men’s Health
The company's commitment to innovation in the field of urology is evident. Joe Biller, Managing Partner at one of the leading investment firms supporting Rivermark, remarked on the company's potential to significantly influence the BPH treatment landscape. Existing therapies often bring about complications such as painful recovery and potential loss of sexual function. This new technology is thoughtfully engineered to address these pressing issues.
About Rivermark Medical
Founded by a practicing urologist, Rivermark Medical aims to establish itself as a leader in the realm of device therapy for benign prostatic hyperplasia. Their flagship FloStent System is designed to be a first-line treatment, ensuring patient safety while minimizing discomfort and complications. Rivermark Medical is dedicated to improving the overall quality of life for individuals affected by BPH.
Frequently Asked Questions
What is the FloStent System?
The FloStent System is a device developed by Rivermark Medical that treats benign prostatic hyperplasia by restoring normal urinary flow through a minimally invasive procedure.
How much funding did Rivermark Medical secure?
Rivermark Medical successfully closed a $30 million Series C financing round to advance their product development initiatives.
Who are the key investors in this funding round?
The financing round was led by American Century Investments and included new investors such as Venture Investors Health Fund and Time BioVentures.
What are the benefits of the FloStent System for patients?
The FloStent System is designed for rapid deployment with quick recovery, offering minimal discomfort and preserving sexual function for patients suffering from BPH.
What is the company’s mission?
Rivermark Medical aims to develop innovative solutions for BPH treatment, improving patient outcomes and quality of life through advanced medical technology.
